<code id='D396A3CA25'></code><style id='D396A3CA25'></style>
    • <acronym id='D396A3CA25'></acronym>
      <center id='D396A3CA25'><center id='D396A3CA25'><tfoot id='D396A3CA25'></tfoot></center><abbr id='D396A3CA25'><dir id='D396A3CA25'><tfoot id='D396A3CA25'></tfoot><noframes id='D396A3CA25'>

    • <optgroup id='D396A3CA25'><strike id='D396A3CA25'><sup id='D396A3CA25'></sup></strike><code id='D396A3CA25'></code></optgroup>
        1. <b id='D396A3CA25'><label id='D396A3CA25'><select id='D396A3CA25'><dt id='D396A3CA25'><span id='D396A3CA25'></span></dt></select></label></b><u id='D396A3CA25'></u>
          <i id='D396A3CA25'><strike id='D396A3CA25'><tt id='D396A3CA25'><pre id='D396A3CA25'></pre></tt></strike></i>

          Home / explore / Wikipedia

          Wikipedia


          Wikipedia

          author:leisure time    Page View:162
          Roche HQ
          SEBASTIEN BOZON/AFP via Getty Images

          The multibillion-dollar hunt for what many drugmakers hope will be the next big immunotherapy target has had no shortage of twists and tea-leaf-reading. In the wee hours of Wednesday morning, it got another.

          Roche confirmed it accidentally released interim data from a closely watched clinical trial testing whether blocking that target — a protein on T cells known as TIGIT — can enable non-small lung cancer patients to live longer than standard immunotherapy alone.

          advertisement

          The announcement release came hours after Evercore analyst Umer Raffat emailed investors that he had found a presentation on a Roche media portal, presumably uploaded by accident.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In